Hematopoietic Stem Cell TransplantationTransplantation, AutologousStem Cell TransplantationTransplantation, HomologousPeripheral Blood Stem Cell TransplantationTransplantation ConditioningGraft vs Host DiseaseStem CellsMultiple MyelomaCombined Modality TherapyAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeHematologic NeoplasmsBone Marrow TransplantationMelphalanRemission InductionCyclophosphamideHematopoietic Stem Cell MobilizationGraft SurvivalMyeloablative AgonistsRecurrenceSalvage TherapyEtoposideDisease-Free SurvivalTransplantation ChimeraBusulfanHematopoietic Stem CellsTissue DonorsAntigens, CD34Survival RateRetrospective StudiesSurvival AnalysisWhole-Body IrradiationHodgkin DiseaseLymphoma, Non-HodgkinCytarabineGraft vs Leukemia EffectGranulocyte Colony-Stimulating FactorHistocompatibility TestingImmunosuppressive AgentsVidarabineLeukemia, Myeloid, AcuteMesenchymal Stem Cell TransplantationCord Blood Stem Cell TransplantationTime FactorsLiver TransplantationPrognosisEmbryonic Stem CellsFollow-Up StudiesCarmustineGraft vs Tumor EffectLeukemiaCytomegalovirus InfectionsBone Marrow PurgingVincristineNeoplasm, ResidualThiotepaAdult Stem CellsMyelodysplastic SyndromesHistocompatibilityKidney TransplantationAntineoplastic AgentsLymphocyte TransfusionCell TransplantationAntibodies, Monoclonal, Murine-DerivedSiblingsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAmyloidosisPrecursor Cell Lymphoblastic Leukemia-LymphomaLymphoma, Mantle-CellLymphoma, FollicularHepatic Veno-Occlusive DiseaseLymphocyte DepletionBoronic AcidsLymphomaT-LymphocytesAcute DiseaseDexamethasoneChimerismPluripotent Stem CellsAntilymphocyte SerumCell DifferentiationDoxorubicinPyrazinesTransplantationVirus ActivationImmunocompromised HostHematologic DiseasesThalidomideMinor Histocompatibility AntigensAntineoplastic Agents, AlkylatingCytomegalovirusFatal OutcomeLeukapheresisLeukemia, MyeloidProspective StudiesStem Cell NicheHLA AntigensLymphoma, T-Cell, PeripheralMesenchymal Stromal Cells